Medical

UK-based Ockham Biotech has announced that data from a Phase 2b study of its inhaled heparin for the treatment of COPD demonstrate significant improvement in lung function compared to placebo, with improvements maintained for 7… Read more . . .

Pulmatrix has announced that a pilot bioequivalence study of 5 formulations of its PUR0200 DPI for the treatment of COPD has begun enrollment. The company is partnered with Mylan on development of the DPI. According… Read more . . .

Mast Therapeutics says that top-line results from a Phase 2a study of its AIR001 sodium nitrite inhalation solution for the treatment of heart failure with preserved ejection fraction (HFpEF) demonstrated statistically significant change in pulmonary… Read more . . .

Milestone Pharmaceuticals has announced today that its MSP-2017 intranasal calcium channel antagonist has been assigned the unique non-proprietary name “etripamil” by the United States Adopted Name (USAN) Council. The company is developing the etripamil nasal… Read more . . .

Neurelis says that it has received guidance from the FDA regarding clinical trial requirements for the company’s NRL-1 intranasal diazepam for the treatment of acute repetitive seizures in epilepsy patients and is now initiating the… Read more . . .

Turing Pharmaceuticals said that it has received a no objection letter from Health Canada regarding the initiation of Phase 1 trials of TUR-002 intranasal ketamine for the reduction of suicidal ideations and that it expects… Read more . . .

Cipla has announced the launch of a mobile app called “My Breathefree,” which is intended to serve as a “virtual caregiver” for asthma patients in India. The app includes video demonstrations of correct use for… Read more . . .

Discovery Laboratories has announced the initiation of a Phase 2b trial of Aerosurf aerosolized KL4 surfactant to treat respiratory distress syndrome (RDS) in premature infants. The trial, which is expected to enroll up to 250… Read more . . .